| Objective: Mammary cancer is the most familiar malignant tumour of female breast and one of more familiar malignant tumour of surgery, so that many recent studies aimed at the changes of immunity indexes and pathophysiology during mammary cancer. Erythrocyte, as the highet content blood corpuscle in blood, has many erythrocyte complement receptor type 1(CR1) in the surface of its velamen, which has wide biological functions.As an immune index,erythrocyte CR1 has come to people's attention in these latter years.With the occurrence and derelopment of mammary disease,many elements are involved Non-specific immune system of the its organism occupies a pivotal position in the course of the occurrence and development. Wide-expressed CR1 positive cell on erythrocyte not only plays a great role in cellular immunity regulation but also has something to do with the shift of tumor cell. In recent years, it has been a tendency to diagnose and treat mammary cancer. Although some patients hadn't lym phogenous metastasis, 10%-16% patients of the first period died from hematogenous metastasis. Enlarging operation range blindly can't improve curative effect . It is easy to diagnose that clinical symptoms and signs,but how to find and diagnose concealed hematogenous metastasis has been an imperative clinical task. Therefore in this study the percent of haemal CR1 -positive erythrocyte and erythrocyte natural immuneadhesion activity of mammary cancer were measured in order to elucidate the relationship between the expression of erythrocyte CR1 and the occurrence or development of mammary cancer as well as the prognosis of patients' conditions. The percent of CR1-positive erythrocyte maybe provide a new reference index to mammary cancer for the assistant diagnosis and the evaluation of curative effect. Methods: 1. A total of 72 patients with mammary cancer were recruited in this study. These patients were further divided into 27 early and 19 late mammary cancer. At the same time 50 healthy people were selected from women for regular physical examination and 40 benign mammary disease controls(hyperplasia of mammary glands)were choosed. After an overnight fast,2ml blood samples were taken from the elbow vein and put in anticoagulative test tube. Take out 10μl whole blood, mix with 10μl CD35-FITC monoclonal antibody, lay on dark place for 15 min, add to 1% polyformaldehyde 0.5ml, then put them on machine within 24h for test; at same time make FITC-IgG homotype negative controls.Examine 20000 cells and count the percent of CR1 positive cell. 2. Determination of immune adhesion activity. Put 1×108/ml suspension of RB C(red blood cell)50 ul into code. test tube, add self fresh plasma 50ul and 1×106ml tumor cell 100ul to the tube and whirl it fully, lay aside 37℃ in cubator for 30min, then add 0.9% NS 100ul into it, revolve softly and dye it ,then read the glass slide and count the ratio of rosette of tumor cell combined with the trunk of ureath made up with more than 5 RBC.(red blood cells)Results: 1.There was no significant difference in the percent of CR1-positive erythrocyte and erythrocyte natural immune adhesionactivity between healthy controls and benign mammary disease group(P>0.05);2. The percent of CR1-posItI -ve erythrocyte and erythrocyte natural immune adhesion activity in mammary cancer group were significantly lower than healthy controls(p<0.001) and benign mammary disease group(p<0.001), further more the extent of decline were similar;3. The percent of CR1-positive erythrocyte and erythrocyte natural immune adhesion activity of late mammary cancer patients were much lower than early mammary cancer patients, withal the difference was significant (P<0.001). 4.The ratio of high-expressed CR1-positive erythrocyte in mamary cancer is significantly lower than that of healthy controls and benign mammary group; meanwhile, the ratio of middle-low expressed cases is much higher than that of healthy controls and benign mammany cancer. There is significant difference between them.Conclusions: It has be... |
PDF Full Text Request